Bio-Thera Solutions
688177 · SSE STAR Market
Public Market Listing
Live quotes, historical charts, and market capitalization for Bio-Thera Solutions are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
BAT1706(Avzivi) | Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma |
BAT1806(Tofidence) | Approved | IL-6 receptorMonoclonal antibody | Rheumatoid ArthritisCOVID-19 |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
| Phase 1/2 | OX40Monoclonal antibody | Atopic Dermatitis | |
BAT2606No recent activity | Phase 1 | IL-5Monoclonal antibody | Asthma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $36M | — | — | $22M | report ↗ |